IMAC Regeneration Centers Analysis Shows 81% of Patients Report Improvement in Functional Outcomes from Treatment of Musculoskeletal Conditions

Rhea-AI Summary

IMAC Holdings (Nasdaq: IMAC) reported results revealing that approximately 81% of patients at IMAC Regeneration Centers experienced improved movement following treatment for musculoskeletal conditions. An internal analysis evaluated 828 patients from 2017 to 2019, showing an average functional improvement of 40.7%, with scores decreasing from 64.68% to 38.34%. The analysis indicates that IMAC's non-opioid, non-surgical therapies present a viable alternative to conventional treatments. CEO Jeff Ervin highlighted the cost-effectiveness and success rate of their innovative rehabilitation therapies.

Positive

• 81% of patients reported improvement in movement after treatment.
• Average functional ability improved by 40.7% post-treatment.
• High improvement rates across various musculoskeletal conditions, particularly 92% for neck conditions.

Negative

• 8 patients experienced regression in functionality.
• 142 patients showed no change, indicating a portion of patients did not benefit.

BRENTWOOD, Tenn., June 17, 2020 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, today announced results from an extensive internal analysis of treatment outcomes for musculoskeletal conditions performed at IMAC Regeneration Centers, which showed approximately 81% of IMAC patients reported improvement in movement.

IMAC analyzed functional disabilities primarily affecting the knees, lower back, neck, shoulders, hips, legs and ankles. Data was collected from patients during initial examinations, re-examinations and at discharge intervals in patients’ care plans. IMAC examined patient functional improvement following treatment at IMAC Regeneration Centers between 2017 and 2019 utilizing standardized disability indexes for the categories listed above.

A total of 828 patients were evaluated with each patient receiving non-opioid medical treatments in combination with physical therapy. More than 81%, or 678, exhibited improvement in functionality from 1% to 79%. Eight patients regressed at least 1%, and 142 patients showed no change in functional ability. The average starting disability score among all patients evaluated was 64.68%, and the average disability score following treatment was 38.34%, for an average improvement in functional ability of 40.7%.

“We have long believed that the results of our proprietary, non-opioid, non-surgical regenerative rehabilitation therapies for movement restrictions and physical injuries compete favorably with the current standard of care using opioids or surgical intervention, especially as a more affordable and conservative care option,” stated Jeff Ervin, Chief Executive Officer of IMAC.

In IMAC’s analysis, the percentage of patients reporting improvement for each disability category was as follows: 81% of those treated for knee conditions, 81% of those treated for lower back conditions, 92% of those treated for neck conditions, 72% of those treated for shoulder conditions, 78% treated for hip conditions, 86% treated for leg conditions and 80% of those with ankle conditions. Patients included in IMAC’s analysis had a minimum of 20% functional disability for each condition evaluated. The average treatment duration was 80.25 days, and the average patient age was 72.4 years.

Matt Wallis, Chief Operating Officer of IMAC added, “Our success as providers is measured by the number of patients who demonstrate increased movement, greater stability and reduced pain. Our analysis reinforces that our techniques are successful for a significant majority of our patients.”

About IMAC Holdings, Inc.
IMAC Holdings was created in March 2015 to expand on the footprint of the original IMAC Regeneration Center, which opened in Kentucky in August 2000. IMAC Regeneration Centers combine life science advancements with traditional medical care for movement restricting diseases and conditions. IMAC owns or manages 15 outpatient clinics that provide regenerative, orthopedic and minimally invasive procedures and therapies. It has partnered with several active and former professional athletes, opening six Ozzie Smith IMAC Regeneration Centers, two David Price IMAC Regeneration Centers, as well as Mike Ditka IMAC Regeneration Centers and a Tony Delk IMAC Regeneration Center. IMAC’s outpatient medical clinics emphasize its focus around treating sports and orthopedic injuries and movement-restricting diseases without surgery or opioids. More information about IMAC Holdings, Inc. is available at www.imacregeneration.com.

# # #

Safe Harbor Statement
This press release contains forward-looking statements. These forward-looking statements, and terms such as “anticipate,” “expect,” “believe,” “may,” “will,” “should” or other comparable terms, are based largely on IMAC's expectations and are subject to a number of risks and uncertainties, certain of which are beyond IMAC's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, risks and uncertainties associated with its ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the skills and experience necessary to meet customers’ requirements, and its ability to protect its intellectual property. IMAC encourages you to review other factors that may affect its future results in its registration statement and in its other filings with the Securities and Exchange Commission. In light of these risks and uncertainties, there can be no assurance that the forward-looking information contained in this press release will in fact occur.

IMAC Press Contact:
Laura Fristoe
lfristoe@imacrc.com

Investors
Bret Shapiro
(516) 222-2560
brets@coreir.com

Source: IMAC Holdings, Inc.

FAQ

What were the results of IMAC's recent treatment analysis?

IMAC's analysis showed that 81% of patients reported improved movement after treatment, with an average functional improvement of 40.7%.

How many patients were evaluated in IMAC's treatment study?

A total of 828 patients were evaluated in the treatment analysis conducted by IMAC Holdings.

What conditions did IMAC's patients have?

Patients primarily had musculoskeletal conditions affecting the knees, lower back, neck, shoulders, hips, legs, and ankles.

What percentage of patients had improvement for neck conditions?

92% of patients treated for neck conditions reported improvement according to IMAC's analysis.

What is IMAC's approach to treatment?

IMAC specializes in non-opioid and non-surgical regenerative rehabilitation therapies for musculoskeletal conditions.